CeleCor Wins FDA Review for Investigational Heart Attack Drug

Del Mar, California, U.S., September 30, 2026

FDA Accepts Zalunfiban NDA for Review

The FDA’s acceptance of the NDA means the agency has determined that CeleCor’s application is sufficiently complete to proceed through the regulatory review process. The assigned June 18, 2027 PDUFA date provides a target date by which the FDA expects to take action on the application. The milestone follows CeleCor’s completion of its NDA filing on June 24, 2026, after the company generated clinical evidence supporting the investigational therapy in STEMI. Zalunfiban is being developed to address the critical need for rapid treatment of STEMI, where restoring blood flow to the heart as quickly as possible is essential to reducing the risk of death and irreversible cardiac damage. Unlike many established antiplatelet approaches that require administration through other routes, zalunfiban has been specifically designed for subcutaneous injection, potentially enabling administration at the earliest stage of emergency medical care. The candidate targets the platelet GPIIb/IIIa receptor, which plays a central role in platelet aggregation and the formation of blood clots.

Phase 3 Data Support Cardiovascular Drug Program

CeleCor’s NDA submission follows positive findings from the multinational CeleBrate Phase 3 clinical study, whose results were presented at the American Heart Association Scientific Sessions in November 2025 and published simultaneously in The New England Journal of Medicine Evidence. According to CeleCor, the study evaluated rapid administration of zalunfiban at the first point of medical contact in patients experiencing STEMI. The company reported that treatment reduced the risk of cardiovascular events during the 30 days following treatment. The Phase 3 findings form an important part of the evidence package supporting the FDA application. For patients with STEMI, time is a critical factor because a blocked coronary artery can rapidly cause permanent damage to heart muscle. By developing a treatment intended for early subcutaneous administration, CeleCor is pursuing an approach designed to provide antiplatelet therapy before or during transfer to definitive hospital-based care. The potential role of early treatment is particularly relevant in emergency cardiovascular medicine, where minimizing delays can be clinically important.

CeleCor Advances Novel STEMI Treatment

The FDA review represents the latest milestone in CeleCor’s effort to develop a new therapeutic option for acute heart attack treatment. Zalunfiban remains an investigational drug and has not been approved for any use, meaning its safety and efficacy have not yet been established by regulatory authorities. The FDA’s acceptance of the NDA therefore does not constitute approval, but it does move the candidate into a formal regulatory review process. CeleCor’s development strategy centers on improving treatment at the first point of medical contact, when patients with STEMI initially encounter emergency medical services or other healthcare professionals.

The company believes a rapidly administered subcutaneous GPIIb/IIIa inhibitor could potentially complement existing approaches to restoring coronary blood flow and managing acute thrombosis. The upcoming PDUFA action date of June 18, 2027 will be an important milestone for the program as the FDA evaluates the NDA and the available clinical and regulatory evidence. If approved, zalunfiban could represent a new approach to early antiplatelet treatment for STEMI patients. Until that regulatory decision, however, the therapy remains investigational and should not be considered an approved treatment.

Source: CeleCor Therapeutics press release